Guangdong Hybribio Biotech Co Ltd. Stock Analysis 300639.SZ

Guangdong Hybribio Biotech Co., Ltd. engages in the research, development, production, and sale of nucleic acid molecular diagnostic products in China. The company is headquartered in Chaozhou, Guangdong. The company went IPO on 2017-04-12. The firm operates through three segments. The In Vitro Diagnostic Reagents, Supporting Instruments, and Consumables segment focuses on the research, development, and production of nucleic acid detection reagents and associated instrumentation, including product series for cervical cancer screening, genetic susceptibility testing for hearing loss, and others. The Medical Testing Services segment provides medical laboratory services to healthcare institutions, offering a comprehensive range of testing items that encompass genetic and metabolic disorders, infectious diseases, molecular pathology, and oncology diagnostics. The Medical Services segment primarily delivers precise and personalized solutions for health risk assessment, disease treatment, and health management.